md-medicaldata

Authors

 

Biljana Milić ^1,2, Tatjana Ilić ^1,2, Milica Popović ^1,2, Sonja Golubović^1,2, Dejan Ćelić <sup>1,2

1</sup>Klinički Centar Vojvodine, Klinika za nefrologiju i kliničku imunologiju, Novi Sad
²Univerzitet u Novom Sadu, Medicinski fakultet, Novi

 

UDK: 616-002.52-074

The paper was received / Rad primljen: 28.02.2020.

Accepted / Rad prihvaćen: 13.03.2020.

 

Correspondence to:

Biljana Milić,
Puškinova 22, Novi Sad,
021 452213, 0637197561,
e-mail: biljana.milic@ mf.uns.ac.rs

 

 

Sažetak

 

Cilj rada: Utvrditi značaj anti-C1q antitela kao markera aktivnosti sistemskog eritemskog lupusa i lupus nefritisa. Metode:  Ispitivanjem  je obuhvaćeno 97 bolesnika sa sistemskim eritemskim lupusom (SLE) od kojih je 47 imalo biopsijom potvrđen  lupus nefritis, a 50 je bilo bez bubrežne manifestacije ove bolesti. Aktivnost bolesti je određivana putem Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) indeksa aktivnosti. Titar anti-C1q antitela je određivan iz seruma bolesnika komercijalnim enzimskim imunoesejom.  Rezultati:  Bolesnici sa lupus nefritisom su imali viši titar anti-C1q antitela u odnosu na one bez nefritisa (41,12±49,93 prema 19,08±35,15, p<0,01), ali nije utvrđena značajna razlika izmedju bolesnika sa aktivnim i neaktivnim lupus nefritisom  (46,94±54,88 prema 33,25±42,43, p=0,39). Nije utvrđena razlika u pogledu pozitivnog nalaza i titra anti-C1q antitela između bolesnika sa lupus nefritisom u odnosu na patohistološki nalaz bioptata bubrega (p=0,399). Titar anti-C1q antitela je pozitivno korelirao sa SLEDAI indeksom (r=0,36, p<0,01), titrom anti-dsDNA antitela(r=0,44, p<0,01), a negativno sa C3 (r=-0,42, p<0,01) i C4 komponentom komplementa (r=-0,43, p<0,01). Značajna povezanost je utvrđena i sa 24h proteinurijom (r=0,272, p<0,01). Analiza ROC krive je utvrdila prediktivnu sposobnost anti-C1q antitela u raspoznavanju bolesnika sa aktivnim lupus nefritisom u odnosu na ostale bolesnike sa SLE-a (AUC=0,65)(95%ci 0,52-0,77). Zaključak: Titar anti-C1q antitela u SLE-u mogu služiti kao marker bubrežne manifestacije  SLE-a i globalne aktivnosti bolesti  ali ne i aktivnog lupus nefritisa.

 

 

Ključne reči:

sistemski eritemski lupus, lupus nefritis, anti-C1q antitela

 

 

Abstract

 

Objective: The aim of this study was to determine correlation of anti-C1q antibodies with systemic lupus erythematosus and lupus nephritis clinical activity. Methods: 97 SLE patients were studied. 47 had biopsy proven lupus nephritis (LN) and 50 had SLE without renal involvement. Activity of disease was categorized according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score. Levels of anti-C1q antibodies were mesured using comercial enzyme immunoassay.  Results: Patients with lupus nephritis had  higher titres of anti-C1q antibodies than those without renal involvement (41,12±49,93 vs 19,08±35,15, p<0,01), but there was no significant difference between patients with active and non-active renal involvement (46,94±54,88 vs 33,25±42,43, p=0,39). There were no differences in anti-C1q  titres between patients with different renal histopathological findings (p=0,399). Anti-C1q were positively correlated with SLEDAI score (r=0,36, p<0,01), anti ds DNA (r=0,44, p<0,01), and negative with C3 (r=-0,42, p<0,01) and C4 (r=-0,43, p<0,01). Significant correlation was found with 24h proteinuria (r=0,272, p<0,01).  Analysis of receiver operator curves (ROC) underscored the predictive value of anti-C1q (AUC = 0.65) (95%CI 0,52-0,77) in distinguishing patients with active LN Conclusion: Anti-C1q in SLE are associated with renal involvement and disease activity but not specifficaly with active LN..

 

 

Key words:

systemic lupus erythematosus, lupus nephritis, anti-C1q antibodies

 

 

References:

1. Wallace DJ, Hahn BH, editors. Dubois’ Lupus Erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
2. Walport MJ. Complement. First of two parts. N Engl J Med. 2001; 344(14):1058–1066. 
3. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001; 344(15):1140–1144. 
4. Bowness P, Davies KA, Norsworthy PJ, Athanassiou P, Taylor-Wiedeman J, Borysiewicz LK, et al. Hereditary C1q deficiency and systemic lupus erythematosus. Q J Med 1994; 87:455–64. 
5. Trendelenburg M, Lopez-Trascasa M, Potlukova E, Moll S, Regenass S, Fremeaux-Bacchi V, et al.  High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dialysis Transplant 2006; 21: 3115–3121. 
6. Trendelenburg M, Marfurt J, Gerber I, Tyndall A, Schifferli J. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 1999; 42: 187–188
7. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
8. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:28891.
9. Weening JJ, D'Agati VD, Schwartz MM,  Seshan SV, Alpers CE, Appel GB et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241–50.
10. Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Annals of the rheumatic diseases. 2005;64:444–8.
11. Trendelenburg, M, Lopez-Trascasa, M, Potlukova, E. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 2006; 21: 3115–3121.   
12. Moroni G, Radice A, Giammarresi G,  Quaglini S, Gallelli B, Leoni A, et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Annals of the rheumatic diseases. 2009;68:234–7
13. Sinico RA, Rimoldi L, Radice A, Bianchi L, Gallelli B, Moroni G: Anti-C1q autoantibodies in lupus nephritis. Ann N Y Acad Sci 2009; 1173:47-51.
14. Trad B, Ben Hassine H, Khalifa M,  Idriss N, Slama F, Bahri F, et al. Anti-C1q antibodies and systemic lupus erythematosus in the Tunisian population. Pathologie-biologie. 2013;61:113–6.
15. Zhang CQ, Ren L, Gao F, Mu FY, You YQ, Liu YH. Anti-C1q antibodies are associated with systemic lupus erythematosus disease activity and lupus nephritis in northeast of China. Clinical rheumatology; 2011;30:967–73.
16. Yang XW, Tan Y, Yu F, Zhao MH. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant 2012;27:3552–9.
17. Gunnarsson, I., B. Sundelin, M. Heimburger, R. van Vollenhoven , I.Lundberg I, SH.Jacobson et al.. Repeated renal biopsy in proliferative lupus nephritis – predictive role of serum C1q and albuminuria. J. Rheumatol. 2002; 29: 693–699.
18. Siegert, C.E., M.D. Kazatchkine, A. Sjoholm,  R. Wurzner, M. Loos, M. R. Daha.. Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin. Exp. Immunol. 1999; 116: 4–8.
19. Horvath, L., L. Czirjak, B. Fekete,  Jakab L, Pozsonyi T, Kalabay L et al.. High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin. Exp. Rheumatol. 2001;19: 667–672
20. Katsumata Y, Miyake K, Kawaguchi Y, Okamoto Y, Kawamoto M, Gono T et al. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum 2011; 63(8):2436-44.

PDF Mulić M. et al • MD-Medical Data 2020;12(1) 015-019